Europeiska unionen - engelska - EMA (European Medicines Agency)

sanofi winthrop industrie - insulin aspart - diabetes mellitus - drugs used in diabetes - insulin aspart sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Nya Zeeland - engelska - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - lixisenatide 0.05 mg/ml; lixisenatide 0.1 mg/ml - solution for injection - 0.05mg/ml + 0.1mg/ml - active: lixisenatide 0.05 mg/ml excipient: glycerol hydrochloric acid metacresol methionine sodium acetate sodium hydroxide water for injection active: lixisenatide 0.1 mg/ml excipient: glycerol hydrochloric acid metacresol methionine sodium acetate sodium hydroxide water for injection - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with metformin, metformin and sulphonylurea, basal insulin and metformin, basal insulin and sulphonylurea when these, together with diet and exercise, do not provide adequate glycaemic control (see sections clinical trials and precautions) (risk of hypoglycemia) for available data on the different combinations.

Nya Zeeland - engelska - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - lixisenatide 0.05 mg/ml - solution for injection - 0.05 mg/ml - active: lixisenatide 0.05 mg/ml excipient: glycerol hydrochloric acid metacresol methionine sodium acetate sodium hydroxide water for injection - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with metformin, metformin and sulphonylurea, basal insulin and metformin, basal insulin and sulphonylurea when these, together with diet and exercise, do not provide adequate glycaemic control (see sections clinical trials and precautions) (risk of hypoglycemia) for available data on the different combinations.

Nya Zeeland - engelska - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - lixisenatide 0.1 mg/ml - solution for injection - 0.1 mg/ml - active: lixisenatide 0.1 mg/ml excipient: glycerol hydrochloric acid metacresol methionine sodium acetate sodium hydroxide water for injection - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with metformin, metformin and sulphonylurea, basal insulin and metformin, basal insulin and sulphonylurea when these, together with diet and exercise, do not provide adequate glycaemic control (see sections clinical trials and precautions) (risk of hypoglycemia) for available data on the different combinations.

Singapore - engelska - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - insulin glulisine - injection, solution - 3.49 mg

Singapore - engelska - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - insulin glargine - injection - 100 iu/ml

Malaysia - engelska - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sanofi-aventis (malaysia) sdn. bhd. - insulin glargine -

Singapore - engelska - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - furosemide - injection - 20 mg/2 ml

Israel - engelska - Ministry of Health

sanofi - aventis israel ltd - insulin lispro - solution for injection - insulin lispro 100 u/ml - insulin lispro - admelog is indicated for the treatment of adults with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. admelog is also indicated for the initial stabilisation of diabetes mellitus.

Israel - engelska - Ministry of Health

sanofi - aventis israel ltd - lixisenatide - solution for injection - lixisenatide 10 mcg / 0.2 ml - lixisenatide - for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.